Mizumoto Junki
Department of Medical Education Studies, International Research Center for Medical Education, Graduate School of Medicine, The University of Tokyo, Tokyo, JPN.
Cureus. 2023 Sep 13;15(9):e45181. doi: 10.7759/cureus.45181. eCollection 2023 Sep.
A male in his 70s developed a rash on his lower abdomen after changing his subcutaneous injection drug from dulaglutide to tirzepatide. The rash diminished after stopping tirzepatide injection. This case illustrated that tirzepatide can potentially lead to an injection site rash, despite another glucagon-like peptide-1 (GLP-1) receptor agonist (RA) being used without adverse reactions. Injection site reactions are one of the potential adverse events associated with GLP-1 RA use. To the best of our knowledge, this is the first reported case of tirzepatide-induced injection site reaction.
一名70多岁的男性在将皮下注射药物从度拉糖肽换成替尔泊肽后，下腹部出现皮疹。停止注射替尔泊肽后皮疹消退。该病例表明，尽管使用另一种胰高血糖素样肽-1（GLP-1）受体激动剂（RA）未出现不良反应，但替尔泊肽仍可能导致注射部位皮疹。注射部位反应是与使用GLP-1 RA相关的潜在不良事件之一。据我们所知，这是首例报道的替尔泊肽引起的注射部位反应病例。
